Lineage Cell Therapeutics Stock

Lineage Cell Therapeutics Dividend 2024

Lineage Cell Therapeutics Dividend

0 USD

Lineage Cell Therapeutics Dividend yield

Ticker

LCTX

ISIN

US53566P1093

WKN

A2PP89

How much dividend does Lineage Cell Therapeutics 2024 pay?

According to the latest status from October 2024, Lineage Cell Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current Lineage Cell Therapeutics price of 0.86 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Lineage Cell Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Lineage Cell Therapeutics Dividend Safe?

Lineage Cell Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, Lineage Cell Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Lineage Cell Therapeutics's Dividend Distributions

Lineage Cell Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Lineage Cell Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Lineage Cell Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Lineage Cell Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Lineage Cell Therapeutics Aktienanalyse

What does Lineage Cell Therapeutics do?

Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Lineage Cell Therapeutics stock

How much dividend does Lineage Cell Therapeutics pay?

Over the past 12 months, Lineage Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lineage Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Lineage Cell Therapeutics?

The current dividend yield of Lineage Cell Therapeutics is .

When does Lineage Cell Therapeutics pay dividends?

Lineage Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lineage Cell Therapeutics?

Lineage Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Lineage Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lineage Cell Therapeutics located?

Lineage Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lineage Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lineage Cell Therapeutics from 10/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2024.

When did Lineage Cell Therapeutics pay the last dividend?

The last dividend was paid out on 10/12/2024.

What was the dividend of Lineage Cell Therapeutics in the year 2023?

In the year 2023, Lineage Cell Therapeutics distributed 0 USD as dividends.

In which currency does Lineage Cell Therapeutics pay out the dividend?

The dividends of Lineage Cell Therapeutics are distributed in USD.

Andere Kennzahlen von Lineage Cell Therapeutics

Our stock analysis for Lineage Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lineage Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.